Category Archives: Business of Biotech

XOMA Collaboration with Arana Therapeutics

XOMA Ltd. (Nasdaq:XOMA) and Arana Therapeutics Limited, a wholly-owned subsidiary of Cephalon, Inc. (Nasdaq:CEPH) will collaborate on multiple proprietary XOMA antibody R&D technologies, including a new antibody phage display library, and a suite of integrated information and data management systems. Arana will pay XOMA a fee of $6 million and XOMA will receive milestone payments and royalties on product sales. The proprietary antibody library covered by the collaboration is one of a series of proprietary Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

PTC Therapeutics Announces Phase III Trial of Ataluren

PTC Therapeutics, Inc. (PTC) initiated a Phase III trial of ataluren, an investigational protein restoration therapy for patients with nonsense mutation cystic fibrosis (nmCF). Ataluren is the first investigational drug designed to address the underlying cause of nonsense mutation cystic fibrosis. The primary objective of the registration-directed double-blind, placebo-controlled study is to evaluate whether ataluren can improve lung function, as measured by forced expiratory volume in one second (FEV1), in patients with nmCF. An orally Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , ,

The latest from Trubion Pharmaceuticals

An interview with Dr. Peter A. Thompson, MD, FACP, President, CEO, & Chairman of the Board of Directors of Trubion Pharmaceuticals: What is one aspect of your company that you feel would be most attractive or exciting to investors? We currently have three product candidates in the clinic with two, strategic collaborations underlying their development – Wyeth for our CD20 programs and Facet for our CD37 programs. Data disclosures later this year from key clinical trials Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Forbes on Flu

Forbes’ Jonathan Fahey wrote an excellent article on influenza and the H1N1 virus this morning. The article is significant for a couple reasons. First, he captures the overall situation so just in case you haven’t read a story or heard about H1N1 yet (and have been living under a rock), you get the full picture quickly and succinctly. Even if you have read about it, it’s always nice to get a quick recap just to Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Trubion Collaboration with Facet Biotech

Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) and Facet Biotech Corporation (Nasdaq: FACT) recently announced an agreement for the joint development and commercialization of TRU-016, a product candidate in phase 1 clinical development for chronic lymphocytic leukemia. TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical (SMIP(TM)) protein therapeutic. The collaboration agreement includes TRU-016 in all indications and all other CD37-directed protein therapeutics.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,